GO:0032423 regulation of mismatch repair: DNA Repair Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032423 regulation of mismatch repair describes any process that modulates the frequency, rate or extent of mismatch repair, a key DNA repair pathway.
• Mismatch repair (MMR) is regulated at multiple levels, including histone code and posttranslational modifications, as well as by CDK-independent D-type cyclins [2,5].
• Deficient MMR leads to microsatellite instability (MSI), a hallmark of certain colorectal and other cancers.
• MMR-deficient tumors often respond to immune checkpoint inhibitors such as nivolumab, highlighting the clinical importance of MMR regulation.
• Emerging regulators include CNOT6 and DHX9, which modulate MMR and influence sensitivity to targeted therapies [3,8].
• Studying regulation of MMR requires integrated approaches such as CRISPR screening, transcriptomics, and functional assays [1,6].
Description
Mismatch repair (MMR) is a highly conserved DNA repair pathway that corrects base-base mismatches and insertion-deletion loops arising during DNA replication. The regulation of mismatch repair (GO:0032423) encompasses any process that modulates the frequency, rate or extent of this repair, ensuring genomic stability. Dysregulation of MMR is directly linked to microsatellite instability (MSI) and cancer predisposition, making it a critical area of research. Understanding how MMR is regulated provides insights into tumorigenesis and therapeutic opportunities, particularly in the context of immunotherapy. This article explores the biological processes, key genes, and experimental models used to study regulation of mismatch repair.
regulation of mismatch repair At A Glance
| GO ID | GO:0032423 |
|---|---|
| GO term | regulation of mismatch repair |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of mismatch repair |
| Related processes | DNA repair, DNA replication, genomic stability |
| Key regulators | Histone modifications, posttranslational modifications, D-type cyclins, CNOT6, DHX9 |
| Disease relevance | Microsatellite instability, colorectal cancer, immunotherapy response |
What Is GO:0032423?
GO:0032423 regulation of mismatch repair is defined as any process that modulates the frequency, rate or extent of mismatch repair. In other words, it includes all molecular events that control how efficiently the MMR machinery detects and repairs DNA mismatches, thereby maintaining genomic integrity.
Why Is regulation of mismatch repair Important in Cell Biology?
Regulation of mismatch repair is essential for maintaining genomic stability, and its dysfunction is a driving force in cancer development. MMR deficiency leads to microsatellite instability (MSI), which is observed in a subset of colorectal cancers and other malignancies. Importantly, MMR status predicts response to immune checkpoint inhibitors, as demonstrated in clinical trials with nivolumab. Therefore, understanding the regulatory mechanisms of MMR is crucial for developing biomarkers and therapeutic strategies.
• MMR regulation prevents mutations that could lead to cancer.
• Defective MMR causes microsatellite instability (MSI), a key biomarker in colorectal cancer.
• MMR-deficient tumors show enhanced response to immune checkpoint blockade.
• Regulation occurs via histone code and posttranslational modifications.
• D-type cyclins regulate MMR independently of CDK activity.
• CNOT6 has been identified as a novel regulator of DNA mismatch repair.
• DHX9 inhibition selectively targets MSI cancers with deficient MMR.
• DNA sensing in MMR-deficient tumor cells is essential for anti-tumor immunity.
• Spatially organized immune hubs in colorectal cancer are influenced by MMR status.
• Understanding MMR regulation aids in designing personalized therapies.
What Happens During regulation of mismatch repair?
Histone Code and Posttranslational Modifications
In simple terms: Chemical tags on histones and proteins can turn MMR on or off.
Regulation of MMR is heavily influenced by the histone code and posttranslational modifications. Specific histone marks and modifications of MMR proteins can alter their recruitment and activity, thereby modulating repair efficiency.
CDK-Independent Role of D-Type Cyclins
In simple terms: D-type cyclins can control MMR even without their usual cell cycle kinase partners.
D-type cyclins (CCND1, CCND2, CCND3) have been shown to regulate DNA mismatch repair in a CDK-independent manner, revealing a non-canonical function that links cell cycle regulators to MMR.
CNOT6 as a Novel Regulator
In simple terms: CNOT6 is a newly discovered protein that helps control MMR.
CNOT6, a deadenylase, has been identified as a novel regulator of DNA mismatch repair, affecting MMR protein levels and potentially influencing cancer cell sensitivity to DNA-damaging agents.
DHX9 and MMR Deficiency
In simple terms: DHX9 is a protein that, when inhibited, can kill cancer cells with defective MMR.
DHX9, an RNA helicase, is a selective vulnerability in microsatellite instable cancers with deficient MMR. Its inhibition abrogates proliferation of these cancers, highlighting a regulatory node that can be exploited therapeutically.
Immune Sensing and MMR Regulation
In simple terms: When MMR is defective, tumor cells trigger immune responses through DNA sensing.
DNA sensing in MMR-deficient tumor cells is essential for anti-tumor immunity. This suggests that MMR status regulates immune recognition, partly through cytosolic DNA accumulation and activation of innate immune pathways.
Key Genes Involved in GO:0032423 regulation of mismatch repair
The following genes and proteins are key players in the regulation of mismatch repair, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MLH1 | Core MMR protein, forms MutLα complex | Loss causes MSI and Lynch syndrome |
| MSH2 | Core MMR protein, forms MutSα complex | Defects lead to MSI and cancer predisposition |
| MSH6 | Core MMR protein, binds mismatches | Mutations associated with MSI |
| PMS2 | Core MMR protein, endonuclease activity | Defects cause MMR deficiency |
| CCND1 | D-type cyclin, regulates MMR independent of CDK | Novel regulator of MMR |
| CNOT6 | Deadenylase, regulates MMR protein levels | Novel MMR regulator |
| DHX9 | RNA helicase, vulnerability in MMR-deficient cancers | Therapeutic target in MSI cancers |
| H2AX | Histone variant, involved in DNA damage response | May influence MMR regulation |
| HDACs | Histone deacetylases, modify chromatin | Regulate MMR via histone code |
| HATs | Histone acetyltransferases | Regulate MMR via histone code |
| UBE2N | Ubiquitin-conjugating enzyme | Posttranslational modification of MMR proteins |
| SUMO1 | Small ubiquitin-like modifier | Posttranslational modification of MMR proteins |
| ATM | DNA damage checkpoint kinase | May indirectly regulate MMR |
| ATR | DNA damage checkpoint kinase | May indirectly regulate MMR |
| CDK4/6 | Cyclin-dependent kinases | Interact with D-type cyclins, but MMR regulation is CDK-independent |
| PD-L1 | Immune checkpoint ligand | MMR deficiency correlates with immune response |
| cGAS | DNA sensor | Mediates immune sensing in MMR-deficient cells |
| STING | Adaptor in DNA sensing pathway | Essential for anti-tumor immunity in MMR-deficient tumors |
How Is regulation of mismatch repair Regulated?
Regulation of mismatch repair is a complex process influenced by various cellular pathways. Histone modifications and posttranslational modifications of MMR proteins directly affect their activity and recruitment. D-type cyclins regulate MMR independently of CDK activity, linking cell cycle progression to repair capacity. Additionally, CNOT6 modulates MMR protein levels, and DHX9 represents a regulatory node whose inhibition is lethal in MMR-deficient cancers [3,8]. These layers of regulation ensure fine-tuned control of MMR in response to cellular stress and DNA damage.
regulation of mismatch repair and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MLH1 | Lynch syndrome, MSI colorectal cancer | Knockout in HCT116 or RKO cells |
| MSH2 | Lynch syndrome, MSI colorectal cancer | Knockout in colorectal cancer cell lines |
| CCND1 | Cancer, MMR regulation | Overexpression and knockout models |
| CNOT6 | Cancer, MMR regulation | Knockdown and knockout in cancer cells |
| DHX9 | MSI cancers with deficient MMR | Small-molecule inhibition and knockout |
Colorectal Cancer and Microsatellite Instability
Deficient MMR leads to microsatellite instability (MSI), a key feature of a subset of colorectal cancers. MSI status is used clinically to diagnose Lynch syndrome and to predict response to immunotherapy. The regulation of MMR is therefore central to colorectal cancer biology.
Immunotherapy Response
MMR-deficient tumors often respond to immune checkpoint inhibitors such as nivolumab. The CheckMate 142 trial demonstrated durable responses in patients with MSI-high colorectal cancer, underscoring the clinical importance of MMR regulation.
Immune Microenvironment
Spatially organized multicellular immune hubs in human colorectal cancer are influenced by MMR status. DNA sensing in MMR-deficient tumor cells is essential for anti-tumor immunity, linking MMR regulation to the tumor immune microenvironment [1,6].
From regulation of mismatch repair-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate MMR? | CRISPR knockout in MMR-proficient and deficient cell lines |
| Does a point mutation in MMR gene affect repair? | Point mutation knock-in using CRISPR |
| Does overexpression of D-type cyclin alter MMR? | Overexpression cell models |
| Does CNOT6 depletion affect MMR protein levels? | Knockout or knockdown models |
| Does DHX9 inhibition selectively kill MSI cells? | Small-molecule inhibitor treatment in MSI cell lines |
| Does MMR status affect immune sensing? | Knockout of MMR genes in tumor cells followed by immune assays |
How to Study the regulation of mismatch repair Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and MMR regulators | Identify novel MMR regulators [3,8] |
| RNA-seq | Transcriptional changes | Measure MMR gene expression |
| Proteomics | Protein abundance and modifications | Detect posttranslational modifications |
| MMR assay | Repair efficiency | Functional validation of regulators |
| Immunofluorescence | Protein localization | Assess MMR protein recruitment |
| Microsatellite instability analysis | MSI status | Diagnose MMR deficiency |
| Immune cell co-culture | Anti-tumor immunity | Evaluate immune response to MMR-deficient cells |
| Spatial transcriptomics | Tissue organization | Study immune hubs in colorectal cancer |
CRISPR Screening
Genome-wide CRISPR screens can identify novel regulators of MMR by selecting for cells that survive DNA-damaging agents or that acquire MSI. This approach has been used to uncover genes like CNOT6 and DHX9 [3,8].
Transcriptomics and Proteomics
RNA-seq and mass spectrometry can reveal changes in MMR gene expression and protein modifications upon perturbation of candidate regulators, providing insights into regulatory networks.
Functional MMR Assays
In vitro mismatch repair assays using cell extracts or purified proteins can directly measure repair efficiency and the impact of regulatory factors.
Immunofluorescence and Imaging
Co-localization of MMR proteins with sites of DNA damage can be visualized by immunofluorescence, allowing assessment of recruitment dynamics and regulation.
How CRISPR Can Be Used to Study GO:0032423 regulation of mismatch repair
Knockout
CRISPR knockout of candidate regulators (e.g., CNOT6, DHX9) can reveal their role in MMR. For example, knockout of CNOT6 affects MMR protein levels and sensitivity to DNA damage. Knockout of core MMR genes like MLH1 induces MSI, providing models for studying MMR deficiency.
Point Mutation
Point mutations in MMR genes (e.g., MLH1, MSH2) can be introduced using CRISPR to model pathogenic variants found in Lynch syndrome. These models help dissect the functional impact of specific mutations on MMR regulation.
Knock-in
Knock-in of tagged MMR proteins (e.g., GFP-tagged MSH6) allows real-time imaging of MMR dynamics and regulation. This approach can reveal how posttranslational modifications affect protein recruitment.
Overexpression
Overexpression of D-type cyclins or other regulators can be achieved via CRISPR activation or lentiviral delivery. Overexpression of CCND1 has been shown to modulate MMR independently of CDK activity.
How EDITGENE Supports regulation of mismatch repair Research
Researchers studying regulation of mismatch repair-related genes often need to determine whether a candidate gene is causally involved in MMR regulation or is merely correlated with MMR status. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of mismatch repair research.
Frequently Asked Questions About regulation of mismatch repair
What is regulation of mismatch repair (GO:0032423)?
It is any process that modulates the frequency, rate or extent of mismatch repair, a DNA repair pathway that corrects replication errors.
What genes are involved in regulation of mismatch repair?
Key genes include MLH1, MSH2, MSH6, PMS2, CCND1, CNOT6, and DHX9, among others [2,3,4,8].
How does mismatch repair deficiency cause cancer?
Defective MMR leads to microsatellite instability and accumulation of mutations, driving cancer development, especially in colorectal cancer.
What is microsatellite instability (MSI)?
MSI is a condition of genetic hypermutability resulting from deficient DNA mismatch repair, often used as a biomarker in cancer.
Why is MMR status important for immunotherapy?
MMR-deficient tumors often respond well to immune checkpoint inhibitors like nivolumab, making MMR status a predictive biomarker.
What is the role of D-type cyclins in MMR?
D-type cyclins regulate MMR independently of CDK activity, linking cell cycle regulators to DNA repair.
How does CNOT6 regulate MMR?
CNOT6 is a deadenylase that affects MMR protein levels and modulates repair efficiency.
What is DHX9 and its link to MMR?
DHX9 is an RNA helicase that is a selective vulnerability in MMR-deficient cancers; its inhibition blocks proliferation of MSI cancers.
How can I study regulation of mismatch repair in the lab?
Approaches include CRISPR knockout/knock-in, overexpression, MMR functional assays, and CRISPR screening [3,5,8].
What services does EDITGENE offer for MMR research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Regulation of mismatch repair (GO:0032423) is a critical biological process that ensures genomic stability and influences cancer development and immunotherapy response. Understanding its molecular players and regulatory mechanisms offers opportunities for therapeutic intervention. EDITGENE's comprehensive CRISPR services empower researchers to dissect these pathways and accelerate discoveries.
References
- 1. Pelka K et al.. 2021. Spatially organized multicellular immune hubs in human colorectal cancer.. Cell 184(18):4734-4752.e20 PMID: 34450029
- 2. Rona G et al.. 2024. CDK-independent role of D-type cyclins in regulating DNA mismatch repair.. Mol Cell 84(7):1224-1242.e13 PMID: 38458201
- 3. Castro J et al.. 2025. A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair.. Cancer Res 85(4):758-776 PMID: 39589774
- 4. Boland CR et al.. 2010. Microsatellite instability in colorectal cancer.. Gastroenterology 138(6):2073-2087.e3 PMID: 20420947
- 5. Li F et al.. 2016. Regulation of mismatch repair by histone code and posttranslational modifications in eukaryotic cells.. DNA Repair (Amst) 38:68-74 PMID: 26719139
- 6. Lu C et al.. 2021. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.. Cancer Cell 39(1):96-108.e6 PMID: 33338425
- 7. Overman MJ et al.. 2017. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.. Lancet Oncol 18(9):1182-1191 PMID: 28734759
- 8. Song P et al.. 2022. CNOT6: A Novel Regulator of DNA Mismatch Repair.. Cells 11(3) PMID: 35159331
